Evidence map›Paper›PMID 33801202›Full record

ArticleJournal of clinical medicine2021

Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis.

Tomotake Shirono, Takashi Niizeki, Hideki Iwamoto, Shigeo Shimose, Hiroyuki Suzuki, Takumi Kawaguchi, Naoki Kamachi, Yu Noda, Shusuke Okamura, Masahito Nakano and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Tomotake ShironoDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.ORCID 0000-0002-2662-6779
Takashi NiizekiDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Hideki IwamotoDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Shigeo ShimoseDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.ORCID 0000-0003-2068-8386
Hiroyuki SuzukiDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.ORCID 0000-0003-2383-5038
Takumi KawaguchiDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.ORCID 0000-0002-7064-4325
Naoki KamachiDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Yu NodaDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Shusuke OkamuraDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Masahito NakanoDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.ORCID 0000-0002-3375-180X
Ryoko KuromatuDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Hironori KogaDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Takuji TorimuraDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, Japan.
Kurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is unsatisfactory. Tumor, host, and treatment factors including hepatic arterial infusion chemotherapy (HAIC) are intricately involved in the progression of ICC. We aimed to identify profiles associated with disease control rate (DCR) and the prognosis of patients with unresectable ICC by decision tree analysis. We analyzed 31 consecutive patients with unresectable ICC (median age, 71 years; the male ratio was 58.1%). Stage IVB occupied 51.6% of patients, and 38.7% and 58.1% of patients were treated with gemcitabine plus cisplatin combination therapy and HAIC, respectively. Profiles associated with prognosis as well as DCR were investigated by decision tree analysis. The median survival time (MST) of the patients was 11.6 months, and the DCR was 70.9%. Multivariate correlation analysis showed that albumin levels and WBC levels were significantly correlated with survival time (albumin, ρ = 0.3572,

Indexed as

cholangiocarcinomainflammationinterventional radiologyprognostic variablereservoir system

Identifiers

PMID33801202
PMCPMC7957874
OpenAlexW3135183203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.